Cardiomyopathy Clinical Trials 2023

What are the top hospitals conducting cardiomyopathy research?

When it comes to advancing the understanding and treatment of cardiomyopathy, several leading hospitals are at the forefront of groundbreaking clinical trials. Brigham and Women's Hospital in Boston leads the pack with nine active trials focused on this heart condition, along with a notable tally of 29 completed studies since their first recorded trial back in 2006. Joining them in Boston is Massachusetts General Hospital, which currently has five ongoing cardiomyopathy trials and an impressive track record of 22 previous trials, starting from as early as 2004.

Across the country in Portland, Oregon Health and Science University is making significant contributions to cardiomyopathy research with four active clinical trials and a cumulative total of 14 conducted studies since their inaugural trial in 2007. Similarly, Cedars-Sinai Medical Center in Los Angeles boasts four ongoing cardiomyopathy trials and has made valuable progress through its involvement in 16 previous investigations dating back to 2007.

Notably recognized for their expertise in cardiovascular care, Cleveland Clinic also plays a vital role by conducting cutting-edge research into cardiomyopathy. Currently undertaking four active clinical trials for this condition alone while having accomplished an impressive count of35 prior investigations since recording its first trial related to cardiomyopathy way back when i.e., around2005.

These top-tier medical institutions serve as beacons of hope for those affected by cardiomyopathy across various geographic locations. Through their dedicated efforts and innovative approaches to research, they strive towards improving outcomes for patients worldwide battling this concerning heart condition.

Which are the best cities for cardiomyopathy clinical trials?

When it comes to cardiomyopathy clinical trials, several cities emerge as leaders in research and development. Boston, Massachusetts leads the way with 22 active trials investigating treatments like Eplontersen, Tafamidis, and Breastfeeding Observational Cohort. New york, New York follows closely behind with 17 ongoing studies focused on interventions such as Solia S LBB lead and Mitral valve repair. Chicago, Illinois and Philadelphia, Pennsylvania both have 16 active trials exploring options like danicamtiv and Biomarker Guided Intervention. Lastly, Portland, Oregon offers 12 active trials examining potential breakthroughs including Tafamidis and mavacamten. These cities provide individuals with cardiomyopathy access to cutting-edge clinical trials that contribute to advancing care for this condition.

Which are the top treatments for cardiomyopathy being explored in clinical trials?

Exciting advancements are taking place in the realm of cardiomyopathy treatments, with several promising options being explored in current clinical trials. At the forefront is carvedilol, a well-established medication that has shown potential in two active trials and five all-time cardiomyopathy studies since its first listing in 2000. Another contender on the horizon is eplontersen, making waves with two ongoing trials dedicated to cardiomyopathy. Its recent introduction to the medical scene in 2020 has sparked interest and hope for future treatment possibilities. Additionally, an intervention involving a Population Health Coordinator is underway, showing promise as it enters its first trial for cardiomyopathy treatment. Lastly, AAVrh.10hFXN—an adeno-associated virus gene transfer vector—is also entering uncharted territory with one active trial focused specifically on treating this condition. These cutting-edge approaches bring us closer to finding effective solutions for patients battling cardiomyopathy worldwide.

Note: "Intervention: Population Health Coordinator" was not specified as a treatment option but included due to lack of alternative information provided by users

What are the most recent clinical trials for cardiomyopathy?

Exciting advancements are underway in the field of cardiomyopathy, with recent clinical trials offering promising prospects for patients. One such trial focuses on Aficamten (CK-3773274), which investigates different dosages (5 mg, 10 mg, 15 mg, and 20 mg) to determine its efficacy in treating cardiomyopathy. Additionally, RP-A601 is being studied in a Phase 1 trial to evaluate its potential benefits for individuals with this condition. Another notable study explores Cohort 1's impact on cardiomyopathy through a Phase 2 investigation. Mavacamten and Eplontersen are also being examined in separate Phase 3 trials as potential therapies for this cardiac disorder. These exciting developments hold promise for improving the lives of those affected by cardiomyopathy.

What cardiomyopathy clinical trials were recently completed?

Recently completed clinical trials for cardiomyopathy have shown promising results in the search for effective treatments. Notably, Columbia University's trial investigating Empagliflozin reached completion in March 2022. Similarly, Cytokinetics concluded its study on CK-3773274 (10 - 30 mg) in January 2020. Furthermore, Eidos Therapeutics, a BridgeBio company, made significant progress with their acoramidis trial which wrapped up in March 2019. These advancements demonstrate the commitment of researchers and offer hope to individuals affected by cardiomyopathy who are eagerly awaiting new therapeutic options.